Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Denali Therapeutics Inc 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 USA

www.denalitherapeutics.com Employees: 445 P: 650-866-8548

Description:

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.

Key Statistics

Overview:

Market Capitalization, $K 4,264,409
Enterprise Value, $K 4,137,299
Shares Outstanding, K 143,922
Annual Sales, $ 330,530 K
Annual Net Income, $ -145,220 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -107,190 K
EBIT, $ -490,070 K
EBITDA, $ -517,300 K
60-Month Beta 1.40
% of Insider Shareholders 7.90%
% of Institutional Shareholders 92.92%
Float, K 132,552
% Float 92.10%
Short Volume Ratio 0.45

Growth:

1-Year Return 48.72%
3-Year Return -39.61%
5-Year Return 59.03%
5-Year Revenue Growth 155.91%
5-Year Earnings Growth -171.79%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.63 on 11/06/24
Next Earnings Date 11/05/24
Earnings Per Share ttm -2.76
EPS Growth vs. Prev Qtr -6.78%
EPS Growth vs. Prev Year 12.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

DNLI Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -32.93%
Return-on-Assets % -30.04%
Profit Margin % -43.94%
Debt/Equity 0.00
Price/Sales 13.01
Price/Cash Flow N/A
Price/Book 3.26
Book Value/Share 9.16
Interest Coverage -0.40
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar